Inactive Instrument

Genkyotex SA.

Equities

GKTX

FR0013399474

Biotechnology & Medical Research

Genkyotex Sa Reports Earnings Results for the Half Year Ended June 30, 2020

September 17, 2020 at 12:25 pm EDT

Genkyotex SA announced earnings results for the half year ended June 30, 2020. For the half year, the company announced operating loss was EUR 2.850 million compared to EUR 4.750 million a year ago. Net loss was EUR 2.675 million compared to EUR 4.625 million a year ago. Basic loss per share was EUR 0.24 compared to EUR 0.58 a year ago.

Latest news about Genkyotex SA.

Calliditas Therapeutics : Acquires Remaining Stake in Genkyotex	21-10-07	MT
Genkyotex SA(ENXTPA:GKTX) dropped from CAC AllShares Index	21-10-05	CI
Genkyotex SA(ENXTPA:GKTX) dropped from Next Biotech Index	21-10-05	CI
Global markets live: Sanofi, ASML, Apple, United Airlines, Netflix...	21-09-29
Global markets live: Airbnb, Coinbase, Walt Disney,...	21-05-14
Genkyotex Sa Reports Earnings Results for the Full Year Ended December 31, 2020	21-02-18	CI
Genkyotex : Chief Medical Officer Steps Down Amid Start of Phase 2/3 Study in Chronic Liver Disease	21-01-22	MT
Genkyotex SA Announces Update for Near Term Clinical Development Plan for Setanaxib	21-01-22	CI
Genkyotex : Reports Positive Results from Phase One Trial of Anti-fibrosis Drug Setanaxib	21-01-18	MT
Genkyotex Announces Positive Phase 1 Results Demonstrating Favorable Safety and Pharmacokinetic Profile of High-Dose Setanaxib	21-01-18	CI
Calliditas Therapeutics AB (OM:CALTX) completed the acquisition of 37.3% stake in Genkyotex SA.	20-12-10	CI
Genkyotex : Setanaxib Obtains Orphan Drug Designation By European Commission	20-12-08	MT
Genkyotex Announces Board and President Changes	20-11-03	CI
Genkyotex Sa Reports Earnings Results for the Half Year Ended June 30, 2020	20-09-17	CI
Genkyotex Announces the Enrollment of the 1st Patient in the Phase 2 Trial of Setanaxib in Idiopathic Pulmonary Fibrosis	20-09-14	CI
Calliditas Therapeutics AB (OM:CALTX) made a tender offer to acquire 37.3% stake in Genkyotex SA for €12.1 million.	20-08-12	CI
Genkyotex Announces the Dosing of the First Subjects in Its Phase 1 Study with High-Dose Setanaxib	20-06-30	CI
Genkyotex Provides New Clinical Data from the PBC Phase 2 Trial Providing Further Evidence of the Anti-Fibrotic Activity of Setanaxib	20-06-18	CI
Genkyotex Receives Approval From the French Medicines Agency to Initiate a Phase 1 Clinical Study With High-dose Setanaxib	20-05-13	CI
Genkyotex SA Announces Consolidated Earnings Results for the Year Ended December 31, 2019	20-05-04	CI
Certain Common Shares of Genkyotex SA are subject to a Lock-Up Agreement Ending on 3-MAY-2020.	20-05-02	CI
Genkyotex’s Setanaxib Significantly Improves Immunotherapy Including Checkpoint Inhibitors in Multiple Preclinical Cancer Models	20-03-03	CI
Genkyotex Sa Reports Earnings Results for the Full Year Ended December 31, 2019	20-02-27	CI
Genkyotex Reports Progress of Setanaxib Phase 2 Investigator Initiated Trials	19-12-03	CI
Genkyotex Announces FDA Approval of Phase 2 Investigator-Initiated Trial with GKT831 in IPF	19-07-17	CI

Chart Genkyotex SA.

Duration

Period

More charts

Company Profile

GenKyoTex SA is a France-based company involved in the biotechnology sector. The Company focuses on the development of therapies based on selective inhibition of nicotinamide adenine dinucleotide phosphate oxidase (NOX) enzymes, which cause a range of disease processes, such as fibrosis, inflammation, pain processing, cancer development and neurodegeneration. The Company's pipeline includes GKT831, a NOX inhibitor aimed at primary biliary cholangitis (PBC) and fibrosis; GKT771, a NOX inhibitor mainly aimed at inflammatory pain and angiogenesis, and other NOX inhibitors, which target at central nervous system (CNS), hearing loss and oncology.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.77%	42.75B
LONZA GROUP AG	+47.70%	41.61B
MODERNA, INC.	+12.24%	41.34B
CELLTRION, INC.	-8.83%	26.59B
ICON PUBLIC LIMITED COMPANY	+7.44%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-23.01%	18.12B
MEDPACE HOLDINGS, INC.	+30.56%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.82%	11.76B
UNITED THERAPEUTICS CORPORATION	+8.35%	11B

Other Biotechnology & Medical Research